Pioglitazone in the treatment of type 2 diabetes mellitus: U.S. clinical experience

Experimental and Clinical Endocrinology and Diabetes

Volumn 108, Issue SUPPL. 2, 2000, Pages

  Buse, J B ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; Fasting plasma glucose; HbA1c; Pioglitazone; Triglycerides

Indexed keywords

EID: 0000771591     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-8527     Document Type: Article

References (22)

1. Brockley MR, Schneider RL: The onset of blood glucose response in patients with type 2 diabetes treated with pioglitazone. Diabetes 49 (Suppl 1): A99 Abstract 400-P, 2000
2. Egan J, Rubin C, Mathisen A, Pioglitazone 027 Study Group: Adding pioglitazone to metformin therapy improves the lipid profile in patients with type 2 diabetes. Diabetes 48 (Suppl 1): A106-A107 Abstract 459, 1999
3. Egan J, Rubin C, Mathisen A, Pioglitazone 027 Study Group: Combination therapy with pioglitazone and metformin in patients with type 2 diabetes. Diabetes 48 (Suppl 1): A117 Abstract 504, 1999
4. Egan JW, Mathisen AL, Pioglitazone 012 Study Group: The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes. Diabetes 49 (Suppl 1): A105, A425-P, 2000
5. IMS Health: Data on File, Eli Lilly and Company, Indianapolis, IN, USA, June 2000
6. King A: A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 23: 557, 2000
7. Mathisen A, Egan J, Schneider R, Pioglitazone 010 Study Group: The effect of combination therapy with pioglitazone and sulphonylurea on the lipid profile in patients with type 2 diabetes. Diabetes 48 (Suppl 1): A106 Abstract 457, 1999a
8. Mathisen A, Geerlof J, Houser V, Pioglitazone 026 Study Group: The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes. Diabetes 48 (Suppl 1): A102-A103 Abstract 441, 1999b
9. Mathisen A, Rubin C, Study Group - Pioglitazone 011: The long-term effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes. Diabetes 49 (Suppl 1): A361 Abstract 1518-PO, 2000
10. Mathisen AL, Schneider R, Rubin C, Houser V, Pioglitazone 026 Study Group: The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes. Diabetologia 42 (Suppl 1): A227 Abstract 853, 1999
11. National Institute of Diabetes, and Digestive and Kidney Diseases. Diabetes Statistics (NIH Publication No. 99-3892, March 1999). National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland, 1999
12. Prescription Card Systems (PCS), Data on File, Eli Lilly and Company, Indianapolis, IN, USA, June 2000
13. Roper Starch: Data on File, Eli Lilly and Company, Indianapolis, IN, USA, 1999.
14. Rubin C, Egan J, Schneider R, Pioglitazone 014 Study Group: Combination therapy with pioglitazone and insulin in patients with type 2 diabetes. Diabetes 48 (Suppl 1): A110 Abstract 474, 1999
15. Schneider R, Egan J, Houser V, Pioglitazone 010 Study Group: Combination therapy with pioglitazone and sulphonylurea in patients with type 2 diabetes. Diabetes 48 (Suppl 1): A106 Abstract 458, 1999
16. Schneider R, Lessem J, Lekich R, Pioglitazone 001 Study Group: Pioglitazone is effective in the treatment of patients with type 2 diabetes. Diabetes 48 (Suppl 1): A109 Abstract 469, 1999
17. Schneider RL, Mathisen AL, Pioglitazone 001 Study Group: The evaluation of baseline blood glucose levels on glycemic control in pioglitazone-treated patients with type 2 diabetes. Diabetes 49 (Suppl 1): A124 Abstract 505-P, 2000
18. Takeda Pharmaceuticals America, Inc; May 28 1999. Package Insert for ACTOS™ Full Prescribing Information.
19. Takeda Pharmaceuticals America, Inc. Eli Lilly and Company ACTOS Confronting the Challenges and Concerns of Type 2 Diabetes. A Product Monograph, 1999
20. World Health Organization: The World Health Report Geneva, Switzerland, 1998
21. World Health Organization: The World Health Bulletin, Geneva, Switzerland, June 1997
22. Yu S: Effect of pioglitazone on blood glucose following an oral glucose challenge. Diabetes 49 (Suppl 1): A352, Abstract 1476-PO, 2000